Shares of IPSEN (OTCMKTS:IPSEY – Get Free Report) saw strong trading volume on Friday . 10,866 shares traded hands during mid-day trading, an increase of 396% from the previous session’s volume of 2,191 shares.The stock last traded at $48.86 and had previously closed at $50.7044.
Wall Street Analyst Weigh In
Separately, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of IPSEN in a research note on Tuesday, April 14th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold”.
Read Our Latest Report on IPSEN
IPSEN Trading Down 3.6%
IPSEN Company Profile
Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.
The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).
Featured Articles
- Five stocks we like better than IPSEN
- Buffett Spent 60 Years Ignoring Tech and the Bill Is Coming Due
- Excited About Gold But Unsure of Its Trajectory? Try These 3 Approaches
- Dollar at a 3-Year Low: 3 Exporters Quietly Printing Money
- Water Infrastructure: Why This Boring Sector Could Get Exciting
Receive News & Ratings for IPSEN Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IPSEN and related companies with MarketBeat.com's FREE daily email newsletter.
